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In recent years, there has been a significant increase
in the incidence of human fungal infections (60). A
number of factors have been implicated with this
increase, but it is generally accepted that the main
influences relate to the more widespread provision of
new medical practices, such as immunosuppressive
therapy and use of broad spectrum antibiotics, and
invasive surgical procedures such as solid organ or
bone marrow transplantation. Infections may either
be superficial, affecting the skin, hair, nails and
mucosal membranes, or systemic, involving major
body organs (95). The risk of systemic infection ap-
pears to be enhanced in cases where the individual is
already colonized by Candida (71). With regard to
superficial mucosal infections, the continued spread
of HIV infection (29) and the more extensive use of
inhaled steroids (36) have also played significant
roles.
Of the fungi regarded as human pathogens, mem-
bers of the genus Candida are amongst the most
frequently recovered from disease. The Candida
genus is a taxomomic grouping that was originally
used to define yeast-like organisms that were not
considered to have a sexual reproductive life cycle.
Candida contains over 350 heterogeneous species,
but only a minority of these have been implicated in
human disease (Table 1). Infections caused by Can-
dida are collectively referred to in the plural as can-
didoses (singular candidosis) or candidiases (singular
candidiasis). Both terms are used in the literature
although candidosis is preferred to candidiasis by
many due to the -osis part of the word being con-
sistent with the nomenclature used for other fungal
infections.
Of the Candida species isolated from humans,
Candida albicans is the most prevalent in both health
and disease. It is generally accepted that commensal
carriage of this species occurs in approximately 50%
of individuals (81, 107), although figures do vary
depending on the population examined. Mycological
studies have shown that C. albicans represents over
80% of isolates from all forms of human candidosis
(85). However, the so-called non-Candida albicans
Candida species are increasingly recognized as
important agents of human infection (41, 46, 55, 72).
The apparently increased involvement of non-Can-
dida albicans Candida species in human candidoses
may partly relate to improvements in diagnostic
methods, such as the use of primary agars with the
ability to differentiate species, and the introduction
of molecular techniques in the routine diagnosis of
fungaemia (64). However, the increased prevalence of
non-Candida albicans Candida species in disease
could also be a reflection of the inherently higher
level of antifungal drug resistance in some non-
Candida albicans Candida species (39) compared
with C. albicans, as this would promote their persis-
tence, possibly to the detriment of C. albicans, in
mixed-species infections treated with traditional
antifungal agents.
Candidoses have been recognized throughout hu-
man history and are often described as being dis-
eases of the diseased, reflecting the opportunistic
pathogenic nature of Candida. Whilst Candida spe-
cies are generally regarded as harmless members of
the healthy commensal microflora of humans,
infection can arise if a colonized individual becomes
immunocompromised.
Candida species have been encountered in a wide
spectrum of diseases, and almost all human body
organs can become infected (79). Systemic infections
are rare, but are serious when they do occur, with
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mortality rates of up to 60% (22, 62). The incidence of
systemic fungal infection has increased in recent
decades, although exact figures are difficult to
ascertain as most are only diagnosed following au-
topsy. However, in the past 10 years, a fivefold in-
crease in candidaemia has been reported (14), and
the current incidence of candidaemia per 1,000
admissions in Europe ranges from 0.17 to 20
depending on the country and patient group studied
(60). Particularly susceptible patients are those
suffering from leukaemia or recipients of haemato-
poietic stem cell transplants (i.e. bone marrow
transplants) (85). However, the vast majority of
infections remain superficial, affecting moist muco-
sal membranes, particularly of the vagina and oral
cavity (Fig. 1). More recently, it has been suggested
that Candida species may be causative agents in
some diseases of the mouth other than candidosis,
including oral cancer (109), burning mouth syn-
drome (102), taste disorders (98) and endodontic
disease (74), although the basis of these associations
remains uncertain.
There is little evidence for yeast involvement in
periodontal disease, with bacterial species such as
Porphyromonas gingivalis, Tannerella forsythia and
Aggregatibacter actinomycetemcomitans being the
most frequently associated periodontal pathogens
(54). There have been some reports in the literature
linking the presence of Candida with the clinical
condition of linear gingival erythema that is occa-
sionally seen in HIV-infected patients (40, 119).
However, a causative role for Candida has not been
Table 1. Candida species associated with human
infection
Candida species* Reference
Candida albicans (11)
Candida dubliniensis (114)
Candida parapsilosis (115)
Candida tropicalis (41)
Candida glabrata (63)
Candida kefyr
(pseudotropicalis)
(23)
Candida lusitaniae (6)
Candida krusei (104)
Candida guilliermondii (71)
Candida utilis (44)
Candida lipolytica (108)
Candida famata (56)
Candida haemulonii (52)
Candida rugosa (113)
*The list is an indication of the typical Candida species that have been asso-
ciated with human infection but is not intended to be comprehensive of all
pathogenic species.
A
C
B
D
Fig. 1. Clinical presentation of
primary oral candidosis: (A) pseudo-
membranous candidosis, (B) acute
erythematous candidosis, (C) chron-
ic hyperplastic candidosis, and (D)
chronic erythematous candidosis.
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confirmed and the condition is rarely observed today,
possibly due to the frequent use of systemic anti-
fungal agents in these patients.
Interestingly, whilst the microflora of peri-
implantitis resembles that of chronic periodontitis,
Candida has been recovered from 55% of peri-im-
plant lesions and appears to be absent at healthy
implant sites (61). However, the aetiological
involvement of Candida in peri-implantitis requires
further longitudinal studies.
Virulence factors of Candida
Infection models of candidosis in animals suggest
that C. albicans is the most pathogenic species, and
in vitro investigations indicate that it also expresses
higher levels of putative virulence factors compared
with other Candida species. Several potential viru-
lence factors have been proposed in the pathoge-
nicity of Candida species (Table 2), with adhesion to
host surfaces, secretion of proteinases and hyphal
formation apparently the most significant.
Adherence of Candida to host surfaces
Adherence of Candida to host surfaces is required for
initial colonization and contributes to persistence of
the organism within the host. Candida cells adhere to
several host cell types, including epithelial, endothe-
lial and phagocytic cells. Among the many adhesins
expressed by C. albicans, agglutinin-like sequence
proteins have been implicated in pathogenesis and
biofilm formation (78). These cell wall-bound adhe-
sins bind to diverse mammalian peptide ligands,
causing cellular aggregation through homotypic
adhesion, and also co-aggregate with other microbial
pathogens to mediate polymicrobial infections.
Candida can adhere to the surface of medical devices,
in particular denture acrylic and silicone soft liners,
which often promotes biofilm formation.
Secretion of hydrolytic enzymes by
Candida
Candida species secrete several hydrolytic enzymes
associated with pathogenicity, including secreted
aspartyl proteinases, phospholipases, lipases, phos-
phomonoesterase and hexosaminidase (80). Of these
enzymes, the secreted aspartyl proteinases have at-
tracted most interest and are widely considered to be
central to the development of Candida infection. In
contrast with other types of proteinases, secreted
aspartyl proteinases show proteolytic activity only
under acid conditions (pH < 4.0). Importantly for
oral infection, the environment under a removable
denture is acidic, which provides conditions suitable
for both production and activity of secreted aspartyl
proteinases. Secreted aspartyl proteinases are only
produced by certain Candida species, with C. albi-
cans secreting nine distinct aspartyl proteinases,
often at much higher levels compared with other
species. Interestingly, strains of C. albicans isolated
from clinically apparent oral candidosis have been
Table 2. Virulence factors associated with Candida and oral candidosis
Virulence factor Effect
Adherence to host surfaces Promotes retention in the mouth
• Relative cell-surface hydrophobicity • Non-specific adherence process
• Cell surface adhesin molecules • Specific adherence mechanisms
Evasion of host defence mechanisms Promotes retention in the mouth
• High-frequency phenotypic switching • Antigenic modification through frequent cell-surface changes
• Hyphal development • impairs phagocytosis
• Secreted aspartyl proteinase production • Secretory IgA destruction
• Binding of complement molecules • Antigenic masking
Invasion and destruction of host tissue Enhances pathogenicity
• Hyphal development • Promotes invasion of oral epithelium
• Secreted aspartyl proteinase production • Host cell and extracellular matrix damage
• Phospholipase production • Damage to host cells
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shown to produce higher levels of secreted aspartyl
proteinases compared with strains obtained from
carriers with no mucosal signs (58). These findings
suggest that strains of C. albicans that are actively
involved in candidosis could be inherently more vir-
ulent than commensal strains, possibly by being able
to upregulate secreted aspartyl proteinase gene
expression. In contrast, there is no conclusive evi-
dence that proteinase activity is always associated
with infection, and this probably reflects the multi-
factorial nature of Candida infections (80). Phos-
pholipases hydrolyse one or more ester linkages of
glycerophospholipids. Phospholipase activity has
been demonstrated for many fungal pathogens,
including Candida species. It has been reported that
the phospholipase activity is enhanced when hyphae
are in direct contact with host tissue.
Morphological transition of Candida
Candida species, in particular C. albicans, can exhibit
morphological alternation from yeast, pseudohyphal
and hyphal forms, depending on environmental
conditions. Hyphae are believed to play an important
role in tissue and biomaterial invasion, and in vitro
research has shown that C. albicans hyphal mutants
and non-C. albicans strains lacking hyphal formation
exhibit lower ability to invade tissue compared with
wild-type C. albicans strains (50). Candida hyphae
also demonstrate increased adherence properties (53,
80, 103) and greater resistance to phagocytosis com-
pared with yeast. Thus hyphal formation is consid-
ered to be significant to the pathogenicity of Candida.
Candida biofilms and infection
Biofilms can be defined as communities of microor-
ganisms, often attached to a surface and encased
within an extracellular polysaccharide matrix that is
produced by the microorganisms (25). The biofilm
state is the preferred mode of growth of microor-
ganisms in natural environments (24), and recent
reports have linked biofilms with over 65% of hos-
pital-acquired infections (28, 51). It has also been
suggested that Candida strains with a high ability to
form biofilms are generally more virulent than others
(79, 104). The explanation for this is likely to be
multifactorial and relate to the differences observed
between biofilm cells and their free-living or plank-
tonic counterparts. Indeed, it is now known that
significant phenotypic differences occur between
biofilm and planktonic lifestyles (8, 28, 73, 91, 92).
Perhaps the most important of these are those factors
that relate to the promotion, persistence and viru-
lence of the organisms within the host environment.
A recent investigation of candidaemia highlighted the
importance of biofilms in infection, with higher
mortality rates evident when a Candida biofilm was
present (116).
In the oral cavity, not only will adherent biofilm
cells be protected from the normal mechanical
flushing action of saliva and gingival crevicular fluid,
but the biofilm itself is a defensive barrier against
penetration of host immune factors and adminis-
tered antimicrobials (43, 121). Candida biofilms were
first shown to exhibit resistance to antifungals by
Hawser & Douglas (43), and this has been reported by
numerous other researchers since (19, 92). The exact
mechanism of biofilm resistance to antifungals
remains unclear, but it is probably multifactorial. The
extracellular polysaccharide of the biofilm could
serve as an inhibitor to diffusion of an antimicrobial
agent or ionically bind the drug as it diffuses through
the biofilm, thereby effectively reducing its bio-
availability (3, 8). A feature of multilayered biofilms is
the reduced activity and growth rates of cells that are
in areas of limited exposure to required gases and
nutrients, and it could readily be envisaged how these
cells would be less susceptible to an antimicrobial
that relies on inhibiting biochemical pathways asso-
ciated with actively growing cells. These cells could
represent the persister cells that have been sug-
gested to be the resistant phenotype within a biofilm
community (59). Conversely, other studies have
demonstrated that biofilm resistance mechanisms
are actually not completely dependent on changes in
growth rates (7), and may be the result of upregula-
tion of particular genes by biofilm cells. Indeed, the
genes encoding ATP-binding cassette (ABC) trans-
porter proteins that are particularly associated with
azole drug resistance by efflux pump mechanisms in
C. albicans have been shown to be upregulated in
biofilms (69, 73).
Involvement of Candida biofilms in human infec-
tion is well recognized, particularly when occurring
on biomaterials used for implantable medical devices
(Fig. 2). Away from the oral cavity, biofilms of Can-
dida on the silicone rubber of artificial voice box
prostheses in laryngectomized patients have been
identified as a major cause of their failure. Urinary
tract infection by Candida in catheterized patients is
associated with biofilm formation on the inner lumen
of the catheter, and other infections including those
of prosthetic heart valves and replacement joints
have also been linked with Candida biofilms (18, 49,
96). Candida colonization of intravascular catheters
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is a major cause of catheter-related infections, and
has the highest associated mortality rate of such
infection (26). Candidal biofilm formation within
haemodialysis and peritoneal dialysis catheters is
frequent, with up to 20% infected (90). Such biofilms
are responsible for candidaemia or Candida perito-
nitis in patients receiving these treatments.
In terms of oral candidosis, the presence of an oral
prosthesis, most frequently an upper denture, is a
major predisposing factor for oral candidosis
(Table 3). Candida are highly adherent to polymeth-
ylacrylate, which is the base material of dentures, and
recent studies have demonstrated that Candida can
also exploit the presence of microfissures and cracks
within the material, thus facilitating retention and
biofilm promotion (120). An increased surface
roughness will also similarly aid colonization of the
denture by Candida. The formation of biofilms on
denture surfaces is promoted by poor oral hygiene,
and practices such as failure to remove the denture
whilst sleeping and poor denture cleansing are
strongly associated with denture biofilms. Further-
more, the abiotic surface of the denture means that
the ability to remove adherent microbes through self-
renewal of surface layers does not occur as would be
encountered on living mucosa. In addition, the static
conditions with respect to lack of salivary flow under
the fitting surface of the denture are also a contrib-
utory factor for biofilm formation, as mechanical
removal of microorganisms by the flushing action of
saliva is limited.
The form of oral candidosis that is most directly
associated with a Candida biofilm is chronic ery-
thematous candidosis, where colonization of the
denture surface in the form of a biofilm is an integral
component of the infection. In chronic erythematous
candidosis, the fitting surface of the denture acts as a
reservoir of infectious Candida cells, which, given
their close proximity to the palatal mucosal surface,
are suitably positioned to cause local infection. Nor-
mally the mucosal surface provides an effective bar-
rier to infection; however, an ill-fitting denture may
cause frictional irritation of the palatal mucosa and
this facilitates invasion of Candida into the superfi-
cial layers of the epithelium. On occasions, a denture
soft liner may be used to cushion the hard acrylic
material of the denture against the mucosa. The soft
liner serves to reduce friction and irritation, and to
distribute the load exerted by the denture on the
mucosa. Unfortunately, silicone rubber (the most
frequently employed material for soft liners) is also a
surface that Candida can readily colonize and
actually invade (16). Therefore, even when use of a
silicone rubber soft liner has improved the fit of a
denture, the clinical signs of denture stomatitis may
not always disappear. This is particularly the case for
patients whose denture cleansing regimens are poor.
In such instances, maintenance of oral hygiene is
vital, and antifungal agents might be considered as
an adjunct in the management strategy. There have
been attempts to incorporate antifungal agents di-
rectly into the soft liner material, but difficulties in
maintaining an adequate release of the agent over
sufficiently long periods have frequently been
encountered (38).
Fig. 2. Scanning electron micros-
copy of Candida biofilms formed on
silicone rubber surfaces for 48 h.
The scale bar in the images corre-
sponds to 10 lm. Original magnifi-
cation, · 5,000.
Table 3. Local and systemic host factors with associated
oral candidosis
Predisposing host factor Reference
Local host factor
Wearing dentures (17)
Steroid inhaler use (36, 37)
Reduced salivary flow (89)
Nutrition (100)
Systemic host factors
Extremes of age (124)
Endocrine disorders,
e.g. diabetes
(111)
Immunosuppression (29)
Receipt of broad-
spectrum antibiotics
(112)
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The wearing of a denture is also a predisposing
factor to other forms of oral candidosis, such as
hyperplastic candidosis and angular cheilitis (2).
Whilst these types of oral candidosis occur at sites
away from the denture biofilm, it is probable that the
increase in Candida numbers resulting from the
presence of a denture is a major contributory factor
in these infections (1).
Most natural host surfaces such as the oral mucosa
have major advantages compared with implanted
biomaterials and other non-shedding surfaces in
preventing Candida colonization and biofilm forma-
tion. Clearly, the innate immune response of the host
will be effective within the oral mucosa, and, as
previously mentioned, the fact that the oral epithe-
lium is continually replenished means that, in order
to colonize the oral mucosa, Candida must be pres-
ent in the mouth in sufficient numbers and with a
high enough growth rate to allow their continued
persistence. In healthy individuals, candidal biofilms
are therefore not generally seen on the palatal or
buccal mucosa, although low-level colonization will
be detected in cases of commensal carriage. In the
event of host debilitation causing an ecological shift
in favour of Candida growth, candidal biofilms may
develop on the mucosa itself (Fig. 3) (27). Indeed, in
cases of pseudomembranous candidosis and hyper-
plastic candidosis, multilayered growth of Candida
adhering to the mucosal surface can be seen using
histological staining methods applied to either
mucosa smears or biopsy sections (Fig. 4).
Candida biofilm formation
As described above, the presence of Candida biofilms
can play a significant role in clinical infection be-
cause of their resilience and resistance to normal host
removal mechanisms and also antimicrobial therapy.
In order to adequately treat and prevent these
infections, it is therefore first necessary to understand
the processes involved in candidal biofilm formation
and growth, which could then lead to the identifica-
tion of suitable targets for therapy.
Candida biofilm formation and infection is a
staged process comprising (i) adherence to the sur-
face, (ii) colonization, proliferation and invasion, and
(iii) detachment of biofilm cells to promote coloni-
zation and infection of distal sites. Altered gene
expression accompanies development of the biofilm,
and such changes can be detected soon after initial
attachment to the surface (75). In the case of
C. albicans, biofilm formation has been reported to
be associated with the upregulation of genes involved
in adherence (such as agglutinin-like sequence genes
and hyphal wall protein 1; Hwp1) (78) and also those
genes involved in amino acid biosynthesis and
metabolism (126).
The initial stage of adhesion of Candida to host
surfaces occurs through the combined effects of
C. glabrata C. tropicalis  
Fig. 3. Confocal laser scanning
microscopy images of (A) Candida
glabrata and (B) Candida tropicalis
colonizing and invading human oral
epithelium after 24 h incubation.
Candida yeast and filaments are
shown in red, and the nuclei of the
epithelial cells appear blue.
Fig. 4. Periodic acid Schiff-stained tissue section of
chronic hyperplastic candidosis showing tissue invading
Candida hyphae (purple-stained filaments).
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non-specific and specific adherence mechanisms.
One key non-specific force in adhesion is the
hydrophobic attraction of candidal surface molecules
to the intended site of attachment. Normally the
surface of a biomaterial will become rapidly coated in
proteinaceous components derived from condition-
ing fluids such as the constituents of saliva. Together
with electrostatic forces, a net attraction will be
generated that brings about the necessary close
proximity between the microorganism and the sur-
face to allow specific adhesion mechanisms to occur,
and several specific Candida adhesin molecules and
host receptors have been described. In the case of
Candida, it is usually the yeast form that is involved
in initial adherence (24).
Once a firm attachment of the yeast to the surface
has become established through specific adhesins
and host receptors, proliferation of Candida may
occur, with growth of the yeast and generation of
filamentous extensions. It is believed that ultimately,
hyphae provide the greatest component of the bio-
film biomass, with the yeast providing a base layer for
their attachment. In vitro studies using confocal laser
scanning microscopy analysis of C. albicans biofilm
formation on reconstituted human oral epithelium
have shown the importance of hyphal production in
the invasion process (13, 67). Cross-linking between
hyphal extensions mediated by interaction of Hwp1
and agglutinin-like sequence surface proteins (78)
might provide additional stability to the biofilm
structure. Candida species produce extracellular
polysaccharide to varying degrees, with large quan-
tities present in biofilms of C. albicans and lower
amounts for Candida glabrata (83). The extracellular
polysaccharide matrix produced by C. albicans bio-
films, whilst composed primarily of carbohydrates,
also includes proteins, hexosamine, phosphorus and
uronic acid (4, 8).
The extent of Candida proliferation is determined
by many factors, including the ability of the host to
elicit innate defensive mechanisms, the inherent
competition for nutrients and space provided by
other members of the oral microflora, and regulation
of biofilm formation by the Candida cells themselves.
There is now clear evidence for the presence of cell-
to-cell signalling molecules in bacterial biofilms that
serve as biofilm density-dependent regulators. These
chemicals are frequently termed quorum sensing
molecules, and include the acyl homoserine lactones
and small peptide regulators produced by Gram-
negative and Gram-positive bacteria, respectively.
The role of quorum sensing molecules in biofilms is
to regulate expression of a variety of genes that can
coordinate not only growth rate, but biofilm detach-
ment, virulence, antimicrobial resistance and even
induction of host cytokines. In the case of Candida
biofilms, two quorum sensing molecules have been
described, namely, farnesol (3,7,11-trimethyl-2,6,10-
dodecatriene-1-ol) and tyrosol (2-[4-hydroxyphenyl]
ethanol), and the concentration and effects of these
molecules on biofilms has been found to be time-
dependent. The recognition of farnesol production by
Candida was the first description of a quorum sens-
ing molecule in a eukaryotic system. Farnesol has
been shown to be an inhibitor of hyphal development
in C. albicans (47, 92, 106), and its accumulation in
mature biofilms is thought to be responsible for
inducing the release or detachment of yeast from the
biofilm (77). Recently, it was reported that C. albicans
also secretes dodecanol, which is a chemical inhibitor
of the yeast-to-hyphal transition (68). In contrast,
tyrosol appears to be an accelerator of candidal fila-
mentation under suitable conditions (21, 47), and
plays an important role in proliferation of the fila-
mentous form after the adherence phase and through
to intermediate biofilm stages (5).
Clinical presentation of oral
candidosis
Oral candidosis is not a single clinical entity, but is
recognized to occur as four distinct primary forms.
These include two transient types, namely pseudo-
membranous candidosis and acute erythematous
candidosis, and two persistent forms, termed chronic
erythematous candidosis and chronic hyperplastic
candidosis. In addition, the long-term immunosup-
pressive state associated with HIV infection ⁄ AIDS
and the more widespread administration of immu-
nosuppressive drugs has resulted in a prolonged form
of pseudomembranous candidosis, which may be re-
ferred to as chronic. Candida has also been implicated
in angular cheilitis and median rhomboid glossitis.
Each type of infection is associated with characteristic
clinical signs and symptoms that are influenced by a
range of predisposing factors (Table 3).
Pseudomembranous candidosis
Pseudomembranous candidosis is synonymous with
the term oral thrush, and is reported in neonates
and the elderly at rates of 5–10% (101). The infection
is characterized by the presence of superficial white
plaques that are easily removed by gentle rubbing of
the lesion (Fig. 1A) (99). The ability to remove these
256
Williams et al.
plaques is a diagnostic feature that differentiates
pseudomembranous candidosis from other forms of
white patch lesions of the oral mucosa. Histological
examination of the plaques reveals fungal elements
in the form of yeast and filamentous forms, together
with epithelial cells.
Acute erythematous candidosis
This condition is often referred to as antibiotic sore
mouth, as it tends to develop following a reduction
in the levels of the bacterial component of the oral
microflora after the receipt of broad-spectrum anti-
biotics. A decrease in bacterial numbers results in
reduced microbial competition for Candida in terms
of nutrition and adherence sites. The clinical signs
and symptoms of acute erythematous candidosis are
therefore a direct consequence of an ecological shift
in the normal homeostatic balance of the microbial
community. Acute erythematous candidosis presents
as a painful reddened lesion, and although the palate
or buccal mucosa may be involved, the most com-
mon site of infection is the dorsum of the tongue
(Fig. 1B). Cessation of antibiotic therapy results in a
return to normal levels of bacteria, which subse-
quently resolves the candidosis without intervention.
Concomitant use of steroid therapy, particularly in
inhaler form, is an additional contributing factor, as
this can create a localized area of immune suppres-
sion within the mucosa that permits overgrowth of
Candida.
Chronic hyperplastic candidosis
This form of candidosis characteristically presents as
a thickened white plaque, most frequently at the
commissure region of the mouth or on the dorsum
of the tongue (Fig. 1C). Of particular concern with
this form of infection is the potential for the devel-
opment of squamous cell carcinoma at lesional
sites, although the role of Candida in the process of
malignant change remains unclear (109, 122). Two
clinical types of hyperplastic candidosis have been
described based on the appearance of the lesion.
Homogeneous hyperplastic candidosis is described
as having smooth white lesions that are notably
distinct from those of heterogeneous hyperplastic
candidosis in which areas of erythema occur
resulting in a nodular, speckled appearance. It has
been suggested that heterogeneous lesions have a
greater likelihood of malignant transformation (12,
94). In contrast to pseudomembranous candidosis,
the white patch lesions of hyperplastic candidosis
do not rub off with gentle rubbing. Hyperplastic
candidosis can only be diagnosed by histopatho-
logical examination of lesional biopsy material,
which reveals candidal hyphae invading the epithe-
lium and an underlying chronic inflammatory cell
infiltrate (125). Uncertainty remains over whether
candidal invasion is the primarily ecological factor
of hyperplastic candidosis, or whether Candida
infection is secondary to the formation of an altered
epithelium. Almost all patients with hyperplastic
candidosis are smokers.
Chronic erythematous candidosis
Commonly known as Candida-associated denture
stomatitis, chronic erythematous candidosis presents
as a reddening of the mucosa beneath the fitting
surface of a denture (Fig. 1D). The infection may
develop under any acrylic denture or intra-oral
appliance, but is almost exclusively encountered on
palatal tissues. Principle host factors associated with
this condition are inadequate oral hygiene, failure to
remove dentures whilst sleeping, or poor denture fit
(32). Chronic erythematous candidosis is the most
prevalent form of oral candidosis, with up to 75% of
denture wearers having clinical signs of this condi-
tion, although the sufferer is often unaware of the
presence of infection (9).
Angular cheilitis
This condition presents as erythematous lesions at
one or more, or usually both of the angles of the
mouth. In addition to Candida, the spectrum of
microorganisms recovered from this condition
includes Staphylococcus aureus and streptococcal
species, either alone or in combination. Therefore,
the exact role that Candida itself plays in angular
cheilitis remains uncertain (110). Often, angular
cheilitis involving Candida occurs in patients with a
pre-existing primary form of oral candidosis, most
frequently chronic erythematous candidosis. The in-
creased level of Candida within the mouth of such
patients is most likely to be the major contributing
factor.
Other oral candidoses
Median rhomboid glossitis is a chronic mucosal
condition that, as its name implies, characteristically
presents as a symmetrically shaped lesion on the
midline of the dorsum of the tongue. Candida can
often be recovered from the surface of the lesion, has
257
Candida biofilms and oral candidosis
and is thus implicated in the aetiology. Furthermore,
resolution of the condition following provision of
systemic antifungal therapy supports the role of
Candida in the infection. As with other forms of oral
candidosis, tobacco smoking and steroid inhaler use
are recognized predisposing factors.
Chronic mucocutaneous candidosis is a rare
condition in which a range of chronic Candida
infections of mucous membranes, skin and nails are
encountered. The principle predisposing factor for
chronic mucocutaneous candidosis is congenital
impaired cellular immunity against Candida.
Management of oral candidosis
Principles of treatment
Successful management of patients with oral candi-
dosis requires identification, and where possible
correction, of the specific underlying predisposing
factors in an individual patient. Without this recog-
nition, subsequent treatment using antifungal
therapy may only result in the temporary relief of
infection, with relapses inevitably following. Instruc-
tions should be provided on appropriate oral hygiene
practices. Use of steroid inhalers should be coupled
with rinsing the mouth with water after administra-
tion. All patients should be advised on the importance
of reduction or cessation of any smoking habits. As
described below, oral hygiene practices are also
essential in removal of candidal biofilms on host
surfaces and oral prostheses.
Any identified nutritional deficiency should be
corrected, and advice provided on dietary habits such
as appropriate carbohydrate intake. However, despite
these interventions, situations arise in which the
underlying cause cannot be resolved, such as HIV
infection or immunosuppressive therapy following
organ or bone marrow transplant. In these circum-
stances, treatment of oral candidosis is based on the
use of antifungal therapy. Details on antifungal
agents are provided below, and Table 4 shows the
typical antifungal drugs and the treatment regimes
used specifically for oral candidosis.
Antifungal agents
Relatively few antifungal drugs are available when
compared to the range of antibiotics that have been
produced, which probably reflects both the relatively
recent recognition of the importance of fungal
infections in humans and the difficulty involved in
developing an agent with activity against a eukaryotic
cell type without problems of associated host cell
toxicity. Antifungal drugs are classified according to
their mode of action: (i) disruption of fungal cell
membranes, as seen with the polyene antifungals
(nystatin and amphotericin), (ii) inhibition of ergos-
terol synthesis, exemplified by the azole group of
antifungals (fluconazole and itraconazole), (iii) inhi-
bition of b-1,3-D-glucan synthesis (echinocandin
antifungals), and (iv) induction of incorrect RNA
synthesis and interference with DNA replication
(5-fluorocytosine).
Polyene antifungals exert their fungicidal activity
by inducing cell membrane porosity following
interaction with the ergosterol component of the
membrane, with the subsequent effect of loss of
cytoplasmic content. Polyenes have a broad spec-
trum of antifungal activity, but, due to their poor
absorption through the gut, their use in treatment of
oral candidosis is extremely limited. However, in view
of the fact that these agents are not absorbed, their
safety profile is good. A specific role for the topical
use of these agents is in cream format for the treat-
ment of chronic erythematous candidosis. Despite
wide use over several decades, the actual incidence of
resistance of Candida to polyenes is rare, but can
sometimes arise through a reduction in the ergosterol
content of cell membranes (105).
Azole antifungals are fungistatic through interfer-
ence with the fungal enzyme lanosterol demethylase,
which is a key enzyme in the biosynthesis of ergos-
terol. Both fluconazole and itraconazole are well ab-
sorbed through the gut, which means that oral
administration is an effective means of systemic
delivery. Furthermore, the effects of fluconazole in
the oral cavity are enhanced as it is secreted in saliva
at levels equivalent to those achieved in the blood.
Fluconazole is the agent of first choice for all forms of
oral candidosis apart from chronic erythematous
candidosis. The clinical effectiveness of agents that
can only be delivered topically, such as amphotericin
or nystatin, is limited due to problems in maintaining
sufficient levels of drug at the site of infection. The
taste of topical agents stimulates salivary secretion,
which rapidly dilutes and removes the antifungal
agent from the mouth. In view of this, their clinical
use is limited. Fluconazole has a good safety profile
when given systemically, with few contra-indications
or side effects. Important interactions occur with
coumarin anticoagulants and sulfonylurea antidia-
betic agents. Acquired resistance to azole antifungals
has emerged in recent years, and certain Candida
species are also inherently resistant to these agents.
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Several mechanisms of azole resistance have been
reported including (i) an alteration in the chemical
structure of the demethylase enzyme, (ii) removal of
the azole from the cell by multidrug transporter
pumps, and (iii) compensation by other sterol syn-
thesis enzymes in membrane biosynthesis. Even in
the absence of a defined resistance mechanism, the
in vitro susceptibility of a given Candida strain often
does not correlate with the subsequent clinical out-
come for patients with oral candidosis. One possible
explanation for this could relate to the phenotypic
differences described above for planktonic and bio-
film cultured cells, as it is the former that are most
frequently used for in vitro antifungal susceptibility
testing.
Management of candidal biofilms
As described previously, the presence of candidal
biofilms reduces the likelihood of removal of organ-
isms by host defence mechanisms and antifungal
agents. Thus appropriate management of biofilms is
essential. There is no single approach that can be
used to specifically counter candidal biofilms, and a
variety of mechanical and chemical methods to im-
prove oral hygiene are generally adopted. Ideally an
anti-biofilm approach will prevent development of
the biofilm in the first instance, as well as being
effective against established biofilms.
Standard oral hygiene practices including tooth-
brushing and the use of mouthwashes are important
Table 4. Recommended antifungal agents for treatment of oral candidosis
PMC AEC CEC CHC Typical adult dose
Topical
administration
Nystatin Yes one lozenge:
100,000 units
q.i.d. · 7–14 days
Suspension: 500,000
units by rinse and
swallow q.i.d. · 7–
14 days
Amphotericin Yes one lozenge (10 mg)
q.i.d. · 10–15 days
Miconazole Yes Oral gel (24 mg ⁄
ml); 5–10 ml q.i.d. ·
7–14 days
Clotrimazole Yes one lozenge (10 mg)
five times per day ·
7–14 days
Systemic
administration
Ketoconazole Yes Yes Yes 200–400 mg ⁄ day ·
7–14 days
Fluconazole Yes Yes Yes 100 mg ⁄ day · 7–
14 days
Itraconazole Yes Yes Yes 200 mg (20 ml) sus-
pension by rinse and
swallow without
food q.i.d. · 7–
14 days 200 mg ⁄
day (capsules taken
with food) · 2–
4 weeks
PMC, pseudomembranous candidosis; AEC, acute erythematous candidosis; CEC, chronic erythematous candidosis; CHC, chronic hyperplastic candidosis. q.i.d.,
four times per day.
Other antifungal agents are available and these may be more frequently used in hospitalized patients.
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tools in oral biofilm removal. Toothbrushing offers a
physical means to combat biofilms (97), but may be
limited to accessible sites within the oral cavity and
can have deleterious effects on acrylic denture sur-
faces if abrasive toothpastes are used. In such cases,
the resulting roughened acrylic surface could, in
theory, be more conducive to subsequent biofilm
formation. It has been suggested that mechanical
toothbrushing may offer an advantage over manual
toothbrushing by having an additional physical
influence on biofilms at sites inaccessible to the
toothbrush bristles, such as interproximal regions.
Potential benefits of sonication include possible
cavitation of surrounding fluids and generation of
shear forces, which then disrupt the biofilm, although
its clinical value remains uncertain (45). The poten-
tial antifungal effects of such shear forces on Candida
are as yet not known. Nevertheless, as dental plaque
contains yeast, toothbrushing will serve to reduce the
level of Candida in the mouth and also maintain
normal levels of mucosal resistance to fungal infec-
tions, which can otherwise be reduced with deterio-
ration in oral hygiene.
A wide variety of mouthwashes have been found
to have anti-candidal activity, including chlorhexi-
dine gluconate, trichlosan and those incorporating
essential oils. Chlorhexidine is a cationic chlor-
ophenyl bisbiguanide and is perhaps the most fre-
quently used mouthwash. Chlorhexidine exhibits a
broad spectrum of antimicrobial activity that
encompasses Candida species (66). It is believed to
bind to negatively charged Candida surfaces, and
induces a loss of structural integrity, decreases
adherence capability and disrupts the cell wall.
Chlorhexidine’s anti-candidal properties are also
retained against Candida that is adhered to acrylic
surfaces (88), and is therefore of value in the treat-
ment of chronic erythematous candidosis. Studies
have shown that 0.2% chlorhexidine gluconate
mouth rinses exhibit clinical benefit in the treat-
ment of acute erythematous and pseudomembra-
nous candidosis (15, 30). However, there are reports
of reduced efficacy of nystatin when used in com-
bination with chlorhexidine gluconate, and therefore
it is often advocated that nystatin treatment be
delayed for 30 min after use of chlorhexidine
mouthwash. The reason for the reduced efficacy has
been proposed to be due to the formation of a low
solubility chlorhexidine-nystatin salt that is less
effective as an antibiotic agent (10).
Essential oil mouthwashes containing a range of
natural plant extracts, including thymol, eucalyptol,
bioflavanoids and tea tree (Melaleuca alternifola) oil
derivatives, have also been shown to have direct
bactericidal and anticandidal activity in vitro (33,
82). It is thought that essential oil mouthwashes kill
microorganisms by cell membrane disruption and
enzyme inhibition (34, 57). As with traditional
antifungal agents, however, the effectiveness of
natural antimicrobials on established biofilms in
the oral cavity is less certain, with incomplete
penetration by the agents being reported (76). The
clinical efficacy of this category of mouthwashes
has been studied, but largely against plaque bac-
teria (35, 84), and therefore the clinical benefits of
these agents in treating oral candidosis remain to
be established.
One of the main problems associated with eradi-
cating a biofilm from a biomaterial implanted within
the body is the difficulty of access for biofilm removal
or biomaterial replacement. Often the latter is the
only option available for the management of infec-
tion of certain indwelling catheters and artificial
voice box devices. With regard to dentures, their
replacement or removal for thorough cleaning is a
relatively easy option. It is essential that dentures are
removed during sleep and ideally immersed in a
suitable antimicrobial cleansing agent. The mouth
rinses described above can all be used, but as the
denture is no longer in contact with the host tissues,
other chemically harsher cleansers such alkaline and
neutral peroxide-type cleansers, hypochlorite, tetra-
sodium EDTA and acidic solutions may also be em-
ployed. Often these agents are used to soak dentures
for a defined time period in an immersion bath,
thereby allowing the cleansing agent to access areas
that are inaccessible by brushing. Prior to use, the
dentures are then rinsed in water to remove the
treatment agent. Furthermore, water at high tem-
peratures may also be incorporated into the cleaning
regime, and the added value of microwaving
water-immersed dentures in the treatment of denture
stomatitis has also been reported (123). Regular
microwaving of dentures, where temperatures
approach 100 C, has been shown to have no adverse
affect on the hardness of the denture resins, although
increased surface roughness was noted (65).
Future strategies for management of
candidal biofilms
One strategy that has been the focus of recent
research is to actually modify the surfaces of
biomaterials so that they are less prone to coloniza-
tion by microorganisms, including Candida (86, 87).
Approaches have included pre-coating biomaterials
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such as silicone rubber or denture acrylic with
chemicals such as silanes, chlorhexidine, histatins
and other surface-modifying groups (20, 87, 88).
In addition, thin-film polymer formulations with
incorporated antifungals (nystatin or amphotericin)
have also recently been shown to inhibit C. albicans
biofilm growth on denture materials (93). Such
approaches will clearly have value in combating
biofilm formation on indwelling medical devices that
are not readily accessible for cleaning and physical
removal of the biofilm, e.g. artificial voice prostheses
(31).
In the future, it may be possible to exploit quorum
sensing molecules to disrupt biofilms as they devel-
op, and it has already been shown that farnesol has
deleterious effects on Candida biofilms, causing
structural instability, even for mature biofilms (48,
92).
Reducing the candidal load within the oral cavity
through the use of probiotic agents is also a consid-
eration. Probiotics are live microorganisms that,
when administered in adequate amounts, confer a
health benefit on the host (70). The concept behind
their use in treatment of oral candidosis would be to
provide microbiological pressure in the local envi-
ronment, either through competition for adherence
sites and nutrients or by creating an environment
that is not conducive to the growth of Candida. There
would also appear to be beneficial effects induced by
probiotics through immune modulation. Previous
studies have used bacterial species such as Strepto-
coccus thermophilus and Lactobacillus bulgaricus to
treat biofilms on indwelling voice prostheses (117,
118), and more recently, in the form of cheeses
containing probiotic organisms, to reduce Candida
load in the oral cavity (42). However, the long-term
ability of probiotics to modulate the normal micro-
flora remains unknown.
Conclusion
Biofilm formation is now a well-recognized phe-
nomenon, and there is clear evidence demonstrating
the importance of this life style in human infection.
Candida is adept at forming biofilms on a range of
surfaces, including natural host tissues and bioma-
terials frequently used in medical devices. Such bio-
films are linked to both systemic and superficial
forms of candidosis in humans. New techniques
including confocal laser scanning microscopy and
molecular analysis tools are enabling elucidation of
the control mechanisms underlying biofilm forma-
tion. By increasing our knowledge of candidal biofilm
formation, potential therapeutic targets may well be
identified that can be used as additional therapies,
alongside standard oral hygiene practices, in pre-
venting oral candidosis.
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